Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-01 4:15 pm Purchase | 2025-04-24 | 13G | Spyre Therapeutics, Inc. SYRE | TANG CAPITAL MANAGEMENT, LLC | 3,200,000 5.300% | 3,200,000 (New Position) | Filing History |
| 2025-02-14 6:06 pm Unchanged | 2024-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Venrock Healthcare Capital Partners III, L.P. | 2,685,448 4.600% | 0 (Unchanged) | Filing History |
| 2025-02-14 4:15 pm Sale | 2024-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | PERCEPTIVE ADVISORS LLC | 2,574,723 4.400% | -297,824 (-10.37%) | Filing History |
| 2025-02-14 09:00 am Purchase | 2024-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | RTW Investments, LP | 3,621,996 6.200% | 1,389,236 (+62.22%) | Filing History |
| 2024-11-14 5:50 pm Sale | 2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE | Venrock Healthcare Capital Partners III, L.P. | 2,685,448 5.300% | -1,049,066 (-28.09%) | Filing History |
| 2024-11-14 4:33 pm Purchase | 2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE | PERCEPTIVE ADVISORS LLC | 2,872,547 5.700% | 265,868 (+10.20%) | Filing History |
| 2024-11-14 4:05 pm Purchase | 2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE | Commodore Capital LP | 1,988,084 3.900% | 54,000 (+2.79%) | Filing History |
| 2024-11-14 09:44 am Sale | 2024-09-30 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Deep Track Capital, LP | 1,000,000 1.970% | -1,184,440 (-54.22%) | Filing History |
| 2024-11-14 09:35 am Sale | 2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE | Avoro Capital Advisors LLC | 885,059 1.700% | -954,079 (-51.88%) | Filing History |
| 2024-11-12 10:34 am Purchase | 2024-11-08 | 13G | Spyre Therapeutics, Inc. SYRE | FMR LLC | 7,623,881 14.999% | 1,040,726 (+15.81%) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE | BlackRock Inc. BLK | 2,663,147 5.200% | 0 (Unchanged) | Filing History |
| 2024-10-23 2:10 pm Purchase | 2024-10-14 | 13G | Spyre Therapeutics, Inc. SYRE | Deutsch Peter E. | 3,550,276 6.990% | 3,550,276 (New Position) | Filing History |
| 2024-10-22 3:24 pm Purchase | 2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE | BlackRock Inc. BLK | 2,663,147 5.200% | 2,663,147 (New Position) | Filing History |
| 2024-06-10 09:48 am Sale | 2024-06-07 | 13G | Spyre Therapeutics, Inc. SYRE | FMR LLC | 6,583,155 12.963% | -1,020 (-0.02%) | Filing History |
| 2024-04-25 4:40 pm Purchase | 2024-04-23 | 13D | Spyre Therapeutics, Inc. SYRE | Fairmount Funds Management LLC | 4,508,579 11.170% | 3,672,120 (+439.01%) | Filing History |
| 2024-04-23 6:22 pm Sale | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Avoro Capital Advisors LLC | 1,839,138 5.100% | -286,459 (-13.48%) | Filing History |
| 2024-03-11 08:19 am Purchase | 2024-03-08 | 13G | Spyre Therapeutics, Inc. SYRE | FMR LLC | 6,584,175 18.213% | 377,724 (+6.09%) | Filing History |
| 2024-02-14 8:47 pm Purchase | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Venrock Healthcare Capital Partners III, L.P. | 3,734,514 9.990% | 3,734,514 (New Position) | Filing History |
| 2024-02-14 4:51 pm Unchanged | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Nantahala Capital Management, LLC | 0 0.000% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:37 pm Purchase | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | EcoR1 Capital, LLC | 887,076 2.500% | 887,076 (New Position) | Filing History |